12 10月 2021 by admin in UncategorizedComments Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer
12 10月 2021 by admin in UncategorizedComments Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer
07 10月 2021 by admin in UncategorizedComments NextCure Announces Publication of Preclinical Data for NC410
05 10月 2021 by admin in UncategorizedComments Pennovation Lab welcomes new tenant Interius BioTherapeutics to its innovation ecosystem
04 10月 2021 by admin in UncategorizedComments NextCure Announces New Appointments to its Board of Directors
29 9月 2021 by admin in UncategorizedComments Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia
28 9月 2021 by admin in UncategorizedComments Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)
27 9月 2021 by admin in UncategorizedComments Syros Announces Appointment of Conley Chee as Chief Commercial Officer
20 9月 2021 by admin in UncategorizedComments Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
13 9月 2021 by admin in UncategorizedComments Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell Therapies for Multiple Diseases
13 9月 2021 by admin in UncategorizedComments Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target
13 9月 2021 by admin in UncategorizedComments Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
10 9月 2021 by admin in UncategorizedComments Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
09 9月 2021 by admin in UncategorizedComments Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML
08 9月 2021 by admin in UncategorizedComments Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1
12 8月 2021 by admin in UncategorizedComments Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights
12 8月 2021 by admin in UncategorizedComments Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates
09 8月 2021 by admin in UncategorizedComments Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors
09 8月 2021 by admin in UncategorizedComments Design Therapeutics Reports GeneTACTM Portfolio Progress and Second Quarter 2021 Results
05 8月 2021 by admin in UncategorizedComments Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
05 8月 2021 by admin in UncategorizedComments Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer
15 7月 2021 by admin in UncategorizedComments Adicet Bio Announces Formation of Scientific Advisory Board
09 7月 2021 by admin in UncategorizedComments 日本中外制药(Chugai)与礼邦医药(Alebund)就 EOS789 开发用于高磷血症治疗达成期权/授权协议
06 7月 2021 by admin in UncategorizedComments NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
01 7月 2021 by admin in UncategorizedComments Tempest Announces Appointment of Christine Pellizzari to its Board of Directors
28 6月 2021 by admin in UncategorizedComments Tempest Closes Merger with Millendo and Completes PIPE Financing
22 6月 2021 by admin in UncategorizedComments Tempest and Millendo Announce Stockholder Approval of Merger
21 6月 2021 by admin in UncategorizedComments NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410
07 6月 2021 by admin in UncategorizedComments Design Therapeutics Expands Board of Directors with Key Appointments
